Össur hf.

Condensed Consolidated Financial Statements

March 31st 2011

Össur hf. Grjóthálsi 5 110 Reykjavík Id-no. 560271-0189

Össur hf.

Condensed Consolidated Financial Statements

March 31st 2011

Table of Contents

Statement by the Board of Directors and President and CEO	2
Financial Ratios	3
Consolidated Income Statements	4
Consolidated Statements of Comprehensive Income	5
Consolidated Balance Sheets	6
Consolidated Statements of Cash Flows	8
Consolidated Statements of Changes in Equity	9
Notes to the Condensed Consolidated Financial Statements	10

Statement by the Board of Directors and President and CEO

The Condensed Interim Consolidated Financial Statements of Össur hf. for the period from 1 January to 31 March 2011 consist of the Financial Statements of Össur hf. and its subsidiaries. The Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34 as adopted by the EU. The Condensed Interim Consolidated Financial Statements are not audited nor reviewed by the Company's auditors.

The total sales of the Ossur Consolidation amounted to USD 97.0 million. The net profit amounted to USD 8.0 million and according to the Balance Sheets the total assets of the Össur Consolidation amounted to USD 594.0 million at the end of period, liabilities were 233.5 million, and equity was 360.5 million.

It is our opinion that these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's assets and liabilities, financial position at 31 March 2011 and operating performance of the period ended 31 March 2011.

The Board of Directors and the President and CEO of Össur hf. have today discussed the Condensed Interim Consolidated Financial Statements for the period from 1 January to 31 March 2011 and confirm them by means of their signatures.

D 1: 1 435 2044	
Reykjavik, 4 May 2011	
Board of Directors	
Niels Jacobsen Chairman of the Board	
Arne Boye Nielsen	Kristján T. Ragnarsson
Þórður Magnússon	Svafa Grönfeldt
President and CEO	

Jón Sigurðsson

Financial Ratios

Consolidated statement						
		YTD 2011	YTD 2010	2010	2009	2008
Income Statement						_
Net sales	USD '000	96,995	86,468	358,538	330,580	346,835
Gross profit	USD '000	61,437	54,088	222,622	201,815	214,203
Operating expenses ²	USD '000	46,335	41,363	163,964	154,071	167,678
Profit from operations	USD '000	15,158	14,143	60,245	48,240	55,958
Net profit	USD '000	8,022	9,693	35,362	22,762	28,488
EBITDA	USD '000	18,270	17,832	74,358	66,988	79,440
Balance Sheet						
Total assets	USD '000	594,014	606,432	607,078	628,217	603,778
Equity	USD '000	360,488	312,457	343,558	312,223	249,648
Net interest-bearing debt (NIBD)	USD '000	138,369	143,180	132,816	157,633	234,281
Cash Flow						
Cash generated by operations	USD '000	12,483	11,401	64,331	85,770	71,460
Cash provided by operating activities	USD '000	1,448	8,276	39,995	69,155	52,835
Cash flows from investing activities	USD '000	(3,370)	(346)	(18,987)	(16,423)	(6,648)
Cash flows from financing activities	USD '000	(32,251)	(14,011)	(45,594)	(4,284)	(30,610)
Free Cash flow	USD '000	(1,874)	7,930	33,389	60,238	46,040
Key figures						
Sales Growth USD	%	12.2	12.0	8.5	(4.7)	4.5
Operating margin	%	15.6	16.4	16.8	14.6	16.0
EBITDA margin	%	18.8	20.6	20.7	20.3	22.9
Equity ratio	%	60.7	51.5	56.6	49.7	41.3
Ratio of net debt to EBITDA ¹		1.8	2.0	1.8	2.4	2.9
Ratio of debt to EBITDA ¹		2.1	3.0	2.5	3.5	3.3
Current ratio		2.0	2.6	1.9	2.3	1.1
Return on equity ¹	%	9.8	8.0	10.2	8.1	11.0
Market						
Market value of equity	USD '000	726,247	700,252	777,593	529,151	349,263
Number of shares	Millions	454	454	454	454	423
Price/earnings ratio, (P/E) 1		22.1	28.1	22.3	23.2	12.3
Diluted EPS ¹	US Cent	7.40	5.48	7.77	5.30	6.73
Diluted Cash EPS ¹	US Cent	10.37	9.32	10.87	9.66	12.29

Notes

^{1.} Financial ratios for YTD 2011 and YTD 2010 are based on operations for the preceding 12 months.

^{2.} Excluding other income.

Consolidated Income Statements for the period 1.1 - 31.3.2011 and 1.1 - 31.3.2010

		0016	-
	Notes	2011 YTD	2010 YTD
Net sales	. 4	96,995	86,468
Cost of goods sold	. <u> </u>	(35,558)	(32,380)
Gross profit		61,437	54,088
Other income	. 6	56	1,418
Sales and marketing expenses		(27,409)	(24,763)
Research and development expenses		(4,621)	(5,102)
General and administrative expenses	· _	(14,305)	(11,498)
Profit from operations		15,158	14,143
Financial income		36	31
Financial expenses		(3,467)	(3,792)
Net exchange rate difference		(862)	2,763
Net financial income / (expenses)	7 _	(4,293)	(998)
Profit before tax		10,865	13,145
		20,000	,
Income tax	. 8	(2,843)	(3,452)
Net profit	_	8,022	9,693
Attributable to	:		
Owners of the Company		7,555	9,562
Non-controlling interests	· _	467	131
	_	8,022	9,693
Earnings per Share			
Basic Earnings per Share		1.77	2.14
Diluted Earnings per Share	·	1.76	2.13

Consolidated Statements of Comprehensive Income for the period 1.1 - 31.3.2011 and 1.1 - 31.3.2010

	Notes	2011 YTD	2010 YTD
Net profit		8,022	9,693
Other comprehensive income			
Gain / (loss) on hedge of a net investment in foreign operations		(1,175)	3,182
Change on cash flow hedges	•	874	1,318
Transl. difference of shares in foreign operations		9,874	(13,218)
Income tax relating to components of other comprehensive income	. <u> </u>	(721)	(810)
Other comprehensive income (net of tax)	. <u> </u>	8,852	(9,528)
Total comprehensive income	_	16,874	165
Att ri butable to	:		
Owners of the Company		16,407	34
Non-controlling interests		467	131
	_	16,874	165

Consolidated Balance Sheets

Assets	
--------	--

	Notes	31.3.2011	31.12.2010
Non-current assets			
Property, plant and equipment	11	33,891	32,089
Goodwill	12	346,732	339,153
Other intangible assets	13	30,683	29,975
Other financial assets	15	4,303	4,160
Deferred tax asset	26	36,294	36,171
	_	451,903	441,548
Current assets			
Inventories	17	49,085	46,261
Accounts receivables	18	58,320	52,322
Other assets	19	11,925	11,349
Assets classified as held for sale	16	1,199	1,199
Bank balances and cash	_	21,582	54,399
	_	142,111	165,530

Total assets 594,014 607,078

31 March 2011 and 31 December 2010

Equity and liabilities

	Notes	31.3.2011	31.12.2010
Equity			
Issued capital	20	201,997	201,997
Reserves	21	10,402	1,420
Retained earnings	22	146,068	138,513
Equity attributable to owners of the Company	<u>-</u>	358,467	341,930
Non-controlling interest in equity	_	2,021	1,628
Total equity	_	360,488	343,558
Non-current liabilities			
Borrowings	24	143,282	158,378
Deferred tax liabilities		14,242	13,691
Provisions	27	5,019	4,718
Other financial liabilities	25	0	1,358
	<u>-</u>	162,543	178,145
Occurred Balance			
Current liabilities			
Borrowings	24	16,669	28,837
Accounts payable		18,419	15,462
Taxes payable		1,644	3,339
Provisions	27	2,522	2,582
Accrued salaries and related expenses		16,990	16,006
Other liabilities	29	14,739	19,149
	_	70,983	85,375
Total equity and liabilities		594,014	607,078
Total equity and nabilities	=	377,014	007,070

Consolidated Statements of Cash Flows for the period 1.1 - 31.3.2011 and 1.1 - 31.3.2010

	Notes	YTD 2011	YTD 2010
Cash flows from operating activities			
Profit from operations		15,158	14,143
Depreciation and amortization	11, 13	3,112	3,689
(Gain) / loss on disposal of assets		7	(1,246)
Change in provisions		204	(554)
Changes in operating assets and liabilities		(5,998)	(4,631)
Cash generated by operations		12,483	11,401
Interest received		206	29
Interest paid	10	(8,609)	(2,294)
Taxes paid	·	(2,632)	(860)
Net cash provided by operating activities	_	1,448	8,276
Cash flows from investing activities			
Purchase of fixed assets	11, 13	(3,386)	(2,512)
Proceeds from sale of fixed assets		64	2,420
Changes in financial assets		(48)	(254)
	_	(3,370)	(346)
Cash flows from financing activities			
Proceeds from long-term borrowings		152,606	0
Repayments of long-term borrowings		(184,782)	(14,011)
Dividends from subsidiaries paid to non-controlling interests	_	(75)	0
	_	(32,251)	(14,011)
Net change in cash		(34,173)	(6,081)
Effects of foreign exchange rate adjustments		1,356	(1,015)
Cash at beginning of period	_	54,399	79,831
Cash at end of period	=	21,582	72,735
Additional information regarding cash flow	10		

Consolidated Statements of Changes in Equity for the period ended 31 March 2011

_	Share capital	Share premium	Statutory reserve	Stock option reserve	Hedging reserve	Translation reserve	Accumulated profits	Attributable to owners of the parent	Non- controlling interests	Total equity
Balance at 1 January 2010	5,068	196,929	1,267	1,415	(8,480)	11,380	103,647	311,226	997	312,223
Net profit							9,562	9,562	131	9,693
foreign operations net of tax					1,081	2,609 (13,218)		2,609 1,081 (13,218)		2,609 1,081 (13,218)
Total comprehensive income for the period	0	0	0	0	1,081	(10,609)	9,562	34	131	165
Stock option charge for the period				69				69		69
Balance at 31 March 2010	5,068	196,929	1,267	1,484	(7,399)	771	113,209	311,329	1,128	312,457
Balance at 1 January 2011	5,068	196,929	1,267	1,944	(4,023)	2,232	138,513	341,930	1,628	343,558
Net profitLoss on hedge of a net investment in							7,555	7,555	467	8,022
foreign operations net of tax					(38)	(984) 9,874		(984) (38) 9,874		(984) (38) 9,874
Total comprehensive income for the period	0	0	0	0	(38)	8,890	7,555	16,407	467	16,874
Payment of dividends Stock option charge for the period				130				0 130	(74)	(74) 130
Balance at 31 March 2011	5,068	196,929	1,267	2,074	(4,061)	11,122	146,068	358,467	2,021	360,488

1. General information

Össur hf. (the Company) is a global orthopaedics company, specializing in the development, manufacturing and sales of prosthetics, bracing and supports and compression therapy products. The principal market areas of the Company are Americas, Europe, Middle East and Africa (EMEA) and Asia, which are served by subsidiaries in the United States, Canada, Sweden, Norway, the Netherlands, UK, France, Australia, Spain, Swiss, S-Africa and China in addition to the Iceland-based parent company.

The main production of the Company is conducted at Össur hf. in Iceland, Gibaud Group (La Tour Finance) in St. Etienne, Trevoux in France, Össur Mexico in Tijuana Mexico and at Össur Americas in California USA. Part of the production is outsourced to Asia.

According to the Company's organizational structure, the consolidation is divided into four main functions; Corporate Finance, responsible for overall financial management; Manufacturing & Operations, responsible for quality control and all production, inventory management and distribution; Research & Development, responsible for product development and product management; Sales & Marketing responsible for sales and marketing through the subsidiaries.

2. Adoption of new and revised Standards

2.1 Statement of compliance

The Condensed Interim Consolidated Financial Statements have been prepared in accordance with IAS 34, Interim Financial Reporting, as adopted by the EU. They do not include all of the information required for full annual Financial Statements, and should be read in conjunction with the Company's Annual Financial Statements for the period ended 31 December 2010.

2.2 Basis of preparation

The Condensed Interim Consolidated Financial Statements have been prepared under the historical cost basis except for the revaluation of financial instruments. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Financial Statements for the period ended 31 December 2010.

3. Quarterly statements

	Q1	Q4	Q3	Q2	Q1
_	2011	2010	2010	2010	2010
Net sales	96,995	94,612	87,437	90,021	86,468
Cost of goods sold	(35,558)	(36,078)	(32,991)	(34,467)	(32,380)
Gross profit	61,437	58,534	54,446	55,554	54,088
Other income	56	(25)	130	64	1,418
Sales and marketing expenses	(27,409)	(25,844)	(22,980)	(23,645)	(24,763)
Research and development expenses	(4,621)	(5,148)	(4,743)	(4,738)	(5,102)
General and administrative expenses	(14,305)	(13,157)	(11,122)	(11,224)	(11,498)
Profit from operations	15,158	14,360	15,731	16,011	14,143
Net financial income /expenses	(3,431)	(4,186)	(3,890)	(3,802)	(3,761)
Net exchange rate difference	(862)	1,155	(6,514)	5,692	2,763
Total financial income/(expenses)	(4,293)	(3,031)	(10,404)	1,890	(998)
Profit before tax	10,865	11,329	5,327	17,901	13,145
Income tax	(2,843)	(3,268)	(1,312)	(4,308)	(3,452)
Net profit	8,022	8,061	4,015	13,593	9,693
EBITDA	18,270	17,876	19,082	19,568	17,832

4. Net sales

C 'C 1	11 .	1 1 1	
Specified	according to	oecoranhical	seements.
Opecifica	according to	Scosiupincui	occincii.

EMEA. 42,994 41,044 Asia. 4,128 3,657 96,995 86,468 Specified according to product lines: Bracing and Supports. 52,317 43,337 Prosthetics. 39,970 37,720 Compression Therapy (Phlebology). 4,456 4,847 Other products. 252 564 96,995 86,468 Specified according to currency: US Dollar, USD. 48,874 40,182 Euro, EUR 30,639 31,440 British Pound, GBP 4,659 4,471 Canadian Dollar, CAD. 4,311 3,810 Swedish Krona, SEK. 2,561 2,934 Norwegian Krona, NOK. 2,100 1,840 Australian Dollar, AUD. 1,102 916 Icelandic Krona, ISK. 250 358 Other. 2,499 517	_	YTD 2011	YTD 2010
Asia	Americas	49,873	41,767
Specified according to product lines: Bracing and Supports. 52,317 43,337 Prosthetics. 39,970 37,720 Compression Therapy (Phlebology). 4,456 4,847 Other products. 252 564 Specified according to currency: 52,995 86,468 Specified according to currency: 48,874 40,182 Euro, EUR. 30,639 31,440 British Pound, GBP. 4,659 4,471 Canadian Dollar, CAD. 4,311 3,810 Swedish Krona, SEK. 2,561 2,934 Norwegian Krona, NOK. 2,100 1,840 Australian Dollar, AUD. 1,102 916 Icelandic Krona, ISK. 250 358 Other. 2,499 517	EMEA	42,994	41,044
Specified according to product lines:	Asia	4,128	3,657
Bracing and Supports		96,995	86,468
Prosthetics. 39,970 37,720 Compression Therapy (Phlebology) 4,456 4,847 Other products. 252 564 96,995 86,468 Specified according to currency: US Dollar, USD. 48,874 40,182 Euro, EUR. 30,639 31,440 British Pound, GBP. 4,659 4,471 Canadian Dollar, CAD. 4,311 3,810 Swedish Krona, SEK. 2,561 2,934 Norwegian Krona, NOK. 2,100 1,840 Australian Dollar, AUD. 1,102 916 Icelandic Krona, ISK. 250 358 Other. 2,499 517	Specified according to product lines:		
Compression Therapy (Phlebology) 4,456 4,847 Other products 252 564 96,995 86,468 Specified according to currency: US Dollar, USD 48,874 40,182 Euro, EUR 30,639 31,440 British Pound, GBP 4,659 4,471 Canadian Dollar, CAD 4,311 3,810 Swedish Krona, SEK 2,561 2,934 Norwegian Krona, NOK 2,100 1,840 Australian Dollar, AUD 1,102 916 Icelandic Krona, ISK 250 358 Other 2,499 517	Bracing and Supports	52,317	43,337
Other products. 252 564 96,995 86,468 Specified according to currency: 48,874 40,182 Euro, EUR. 30,639 31,440 British Pound, GBP. 4,659 4,471 Canadian Dollar, CAD. 4,311 3,810 Swedish Krona, SEK. 2,561 2,934 Norwegian Krona, NOK. 2,100 1,840 Australian Dollar, AUD. 1,102 916 Icelandic Krona, ISK. 250 358 Other. 2,499 517	Prosthetics	39,970	37,720
Specified according to currency:	Compression Therapy (Phlebology)	4,456	4,847
Specified according to currency: US Dollar, USD	Other products	252	564
US Dollar, USD	_	96,995	86,468
British Pound, GBP	Specified according to currency: US Dollar, USD	48,874	40,182
British Pound, GBP	Euro, EUR	30,639	31,440
Swedish Krona, SEK 2,561 2,934 Norwegian Krona, NOK 2,100 1,840 Australian Dollar, AUD 1,102 916 Icelandic Krona, ISK 250 358 Other 2,499 517	British Pound, GBP	4,659	4,471
Norwegian Krona, NOK 2,100 1,840 Australian Dollar, AUD 1,102 916 Icelandic Krona, ISK 250 358 Other 2,499 517	Canadian Dollar, CAD	4,311	3,810
Australian Dollar, AUD. 1,102 916 Icelandic Krona, ISK. 250 358 Other. 2,499 517	Swedish Krona, SEK	2,561	2,934
Icelandic Krona, ISK 250 358 Other 2,499 517	Norwegian Krona, NOK	2,100	1,840
Other	Australian Dollar, AUD	1,102	916
	Icelandic Krona, ISK	250	358
96,995 86,468	Other	2,499	517
		96,995	86,468

5. Segment information

2011	Americas	EMEA	Asia	Eliminations	Consolidated
	YTD 2011	YTD 2011	YTD 2011	YTD 2011	YTD 2011
Sales					
External sales	49,873	42,994	4,128	0	96,995
Inter-segment sales	8,787	20,312	0	(29,099)	0
Total sales	58,660	63,306	4,128	(29,099)	96,995
Result					
Segment result	10,227	3,522	1,409	0	15,158
Financial income/(expenses)					(4,293)
Profit before tax					10,865
Income tax					(2,843)
Net profit					8,022
Balance sheet 31.3.2011					
Assets					
Segment assets	396,775	1,741,603	11,860	(1,556,224)	594,014
Liabilities					
Segment liabilities	163,075	291,379	4,377	(225,305)	233,526
Other information					
Capital additions	1,421	1,907	58	0	3,386
Depreciation and amortization	948	2,093	71	0	3,112

Sales of approximately 5.2 million USD (YTD 2010: 5.3 million USD) arose from sales to the Company's largest customer.

2010	Americas YTD 2010	EMEA YTD 2010	Asia YTD 2010	Eliminations YTD 2010	Consolidated YTD 2010
Sales					
External sales	41,767 5,216 46,983	41,044 17,716 58,760	3,657 0 3,657	(22,932) (22,932)	86,468 0 86,468
Result					
Segment result	7,379	5,527	1,237	0	14,143
Financial income/(expenses)					(998)
Profit before tax					13,145 (3,452)
Net profit					9,693
Balance sheet 31.12.2010					
Assets Segment assets	406,359	856,458	13,167	(668,906)	607,078
Liabilities Segment liabilities	270,710	470,231	6,025	(483,446)	263,520
Other information	Americas	EMEA	Asia	Eliminations	Consolidated
	4.400	4.040	-	^	0.510
Capital additions Depreciation and amortization	1,189 1,328	1,318 2,311	5 50	0	2,512 3,689

6. Other income

Included in other income in YTD 2010 is a gain from sale of an office building in Alisio Viejo, California, amounting to 1.2 million.

7. Financial income / (expenses)

Financial income and (expenses) are specified as follows:

_	YTD 2011	YTD 2010
Financial income		
Interests on bank deposits	23	26
Other financial income	13	5
	36	31
Finance expenses		
Interest on loans	(3,319)	(3,697)
Other financial expenses	(148)	(95)
_	(3,467)	(3,792)
Net exchange rate differences	(862)	2,763
Net financial income / (expenses)	(4,293)	(998)

8. Income tax

Income tax is specified as follows:

	YTD 2011	YTD 2010
Current tax expenses	(3,094)	(2,491)
Deferred tax expenses.	286	(1,091)
Deferred tax reclassified from equity to income	(35)	130
	(2,843)	(3,452)

_	YTD 2011		YTD 20	10
	Amount	%	Amount	%
Profit before taxes	10,865	-	13,145	
Income tax calculated at 20% / 18%	(2,173)	20%	(2,366)	18%
Effect of different tax rates of other jurisdictions	(396)	4%	(687)	5%
Effect of non-deductible expenses	(157)	1%	(260)	2%
Other changes	(117)	1%	(139)	1%
	(2,843)	26%	(3,452)	26%

9. Earnings per share

The calculation of Earnings per Share is based on the following data:

	YTD 2011	YTD 2010
Net profit	8,022	9,693
Total weighted average number of ordinary shares (in thousands)	453,732	453,714
Total average number of shares including potential shares from options (in thousands)	455,107	454,133
Basic Earnings per Share (US cent)	1.77	2.14
Diluted Earnings per Share (US cent)	1.76	2.13
Cash Earnings per Share	2.45	2.95
Diluted Cash Earnings per Share	2.45	2.95

10. Additional information regarding cash flow

	YTD 2011	YTD 2010
Net profit	8,022	9,693
Items not affecting cash	795	(1,214)
Working capital provided by operating activities	8,817	8,479
(Increase) / decrease in inventories	(1,674)	1,348
(Increase) / decrease in receivables	(5,345)	(4,681)
Increase / (decrease) in payables	(350)	3,130
Net cash provided by operating activities	1,448	8,276

Interest paid:

As part of the refinancing, Össur closed its interest rate swap agreement and paid the outstanding fair value of USD 5.4 million. The swap remains effective and the cost will be expensed in the next seven quarters thereafter.

11.	Property,	plant and	equipment
-----	-----------	-----------	-----------

Operating fixed assets are specified	as fo	ollows:
--------------------------------------	-------	---------

	Buildings	Machinery	Fixtures	
2011	& sites	& equipment	& office equip.	Total
Cost	_			_
At 1 January 2011	14,107	34,680	20,801	69,588
Additions	91	755	2,367	3,213
Exchange rate differences	887	706	414	2,007
Eliminated on disposal	0	(184)	(3)	(187)
Fully depreciated assets	0	(646)	(1,461)	(2,107)
At 31 March 2011	15,085	35,311	22,118	72,514
Accumulated depreciation				
At 1 January 2011	8,098	18,631	10,770	37,499
Charge for the period	100	1,003	891	1,994
Exchange rate differences	510	565	278	1,353
Eliminated on disposal	0	(115)	(1)	(116)
Fully depreciated assets	0	(646)	(1,461)	(2,107)
At 31 March 2011	8,708	19,437	10,478	38,623
Carrying Amount:				
At 31 March 2011	6,377	15,874	11,640	33,891
At 31 December 2010	6,009	16,049	10,031	32,089

Depreciation classified by operational category, is shown in the following schedule:

	YTD 2011	YTD 2010
Cost of goods sold	1,031	1,008
Sales and marketing expenses	160	131
Research and development expenses	128	122
General and administrative expenses	675	612
	1,994	1,873

12. Goodwill

_	31.3.2011
Cost	
At 1 January 2010	334,844
Reclass due to previous acquisitions	(1,905)
Arising on acquisition of subsidiaries.	15,332
Exchange rate differences.	(9,118)
At 31 December 2010	339,153
Exchange rate differences.	7,579
At 31 March 2011	346,732
Carrying amount	
At 31 March 2011	346,732
At 31 December 2010	339,153

T1		L - L1 - C - 11 :	11
The carrying amount of a	goodwiii was aliocated	to the following	casn-generating units:

	31.3.2011	31.12.2010
Americas	215,843	215,309
EMEA	127,746	120,726
Asia	3,142	3,118
	346,732	339,153

13. Other intangible assets

	Cust./distrib.			Software and	
	relationships	Patents	Trademarks	other	Total
Cost					_
At 1 January 2011	22,299	12,071	15,598	10,653	60,621
Additions	0	0	0	173	173
Fully depreciated assets	0	(1,400)	0	(54)	(1,454)
Exchange rate differences	993	84	983	260	2,320
At 31 March 2011	23,292	10,755	16,581	11,032	61,660
Amortization					
At 1 January 2011	10,247	10,247	583	9,569	30,646
Charge for the period	577	343	0	198	1,118
Fully depreciated assets	0	(1,400)	0	(54)	(1,454)
Exchange rate differences	428	71	149	19	667
At 31 March 2011	11,252	9,261	732	9,732	30,977
Carrying Amount:					
At 31 March 2011	12,040	1,494	15,849	1,300	30,683
At 31 December 2010	12,052	1,824	15,015	1,084	29,975

Amortization classified by operational category, is shown in the following schedule:

<u> </u>	Y I D 2011	Y 1D 2010
Cost of goods sold	5	0
Sales and marketing expenses	629	794
Research and development expenses	347	792
General and administrative expenses.	137	230
	1,118	1,816

14. The Consolidation

The Consolidation is split into three geographical segments, Americas, EMEA and ASIA. The main operation is carried out in the following companies:

Name of subsidiary	Place of registration and operation	Ownership %	Principal activity
Americas			
Össur Americas, Inc	USA	100%	Manufacturer, sales, distribution and services
Össur Canada, Inc	Canada	100%	Manufacturer, sales, distribution and services
EMEA			
Össur France SAS	France	100%	Manufacturer, sales, distribution and services
Össur Europe, BV	Netherlands	100%	Sales, distribution and services
Össur Nordic, AB	Sweden	100%	Sales, distribution and services
Össur UK Ltd	UK	100%	Sales, distribution and services
Össur Iberia SA	Spain	100%	Sales, distribution and services
Orthopaedic partner Africa (Pty) Ltd	South Africa	100%	Sales, distribution and services
Asia			
Össur Asia Pacific PTY, Ltd	Australia	100%	Sales, distribution and services
Össur Prosth. & Rehabilit. Co, Ltd	China	100%	Sales, distribution and services

Össur hf. operates a finance branch in Switzerland to govern certain intercompany long-term liabilities.

Össur hf established Össur Americas LP and Össur Finance AG during the period. The Company is financed through these two companies.

15. Other financial assets

	31.3.2011	31.12.2010
Investment in associates	21	20
Restricted cash	1,259	1,156
Loans and receivables	3,023	2,984
	4,303	4,160

16. Assets classified as held for sale

At end of 2010 the Company classified its office facilities in Aliso Viejo, California as held for sale. The book value is USD 1.2 million at balance sheet date. Due to uncertainty of timing of the sale the facility has been rented out with a two year lease contract that is transferrable.

Work in progress				
Raw material	17.	Inventories		
Work in progress			31.3.2011	31.12.2010
Finished goods		Raw material	11,606	12,984
A 9,085 46,26		Work in progress	3,586	3,568
In the preparation of the Consolidated Financial Statements, accumulated gains in inventories from intercompany transaction amounting to 9.8 million (YTD 2010: 8.7 million) were eliminated. This has an effect on the income tax expense of the consolidated companies, and an adjustment of 2.7 million (YTD 2010: 2.1 million) is made in the Consolidated Financial Statements to reduce income tax expense to account for this. 18. Accounts receivables 1.609		Finished goods	33,893	29,709
amounting to 9.8 million (YTD 2010: 8.7 million) were eliminated. This has an effect on the income tax expense of the consolidated companies, and an adjustment of 2.7 million (YTD 2010: 2.1 million) is made in the Consolidated Financi Statements to reduce income tax expense to account for this. 18. Accounts receivables			49,085	46,261
Nominal value 31.3.2011 31.12.2010 Nominal value 60,838 54,790 Allowances for doubtful accounts. (1,669) (1,619) Allowances for sales return (849) (849) Allowances for sales return 31.3.2012 31.3.2012 VAT refundable 2,749 2,106 VAT refundable 2,749 2,106 Prepaid expenses. 5,753 5,700 Other 3,423 3,481 11,925 11,342 20. Issued capital Common stock is as follows in millions of shares and USD thousands: Total share capital at 31 March 2011 Shares Nominal value of each share is one Icelandic krona. The share capital has remained unchanged over the period: Share capital premium. Share capital premium. Issued capital.		amounting to 9.8 million (YTD 2010: 8.7 million) were eliminated. This has an effect or consolidated companies, and an adjustment of 2.7 million (YTD 2010: 2.1 million) is made to the consolidated companies.	the income tax	expense of the
Nominal value 60,838 54,790 Allowances for doubtful accounts. (1,669) (1,619) Allowances for sales return (849) (849) 58,320 52,322 19. Other assets VAT refundable 2,749 2,160 Prepaid expenses 5,753 5,750 Other 3,423 3,483 11,925 11,349 20. Issued capital Common stock is as follows in millions of shares and USD thousands: Shares Nominal value Total share capital at 31 March 2011. 454 5,060 Total shares issued and outstanding at balance sheet date is 453,732,008, unchanged from last year. The nominal value of each share is one Icelandic krona. The share capital has remained unchanged over the period: Share Share Share capital premium capital	18.	Accounts receivables		
Allowances for doubtful accounts. (1,669) (1,619 Allowances for sales return. (849) (849 58,320 52,322 19. Other assets 31,3,2011 31,12,2010			31.3.2011	31.12.2010
Allowances for sales return		Nominal value	60,838	54,790
Allowances for sales return		Allowances for doubtful accounts	(1,669)	(1,619)
19. Other assets VAT refundable		Allowances for sales return	` ′	(849)
19. Other assets VAT refundable				
Other			2,749	2,160
20. Issued capital Common stock is as follows in millions of shares and USD thousands: Shares Nominal value Total share capital at 31 March 2011				
20. Issued capital Common stock is as follows in millions of shares and USD thousands: Shares Nominal value Total share capital at 31 March 2011		Out.	-	
Total share capital at 31 March 2011	20.			
Total share capital at 31 March 2011		Common stock is as follows in millions of shares and USD thousands:		
Total shares issued and outstanding at balance sheet date is 453,732,008, unchanged from last year. The nominal value of eac share is one Icelandic krona. The share capital has remained unchanged over the period: Share Share Share Issued capital premium capital			Shares	Nominal value
share is one Icelandic krona. The share capital has remained unchanged over the period: Share Share Issued capital premium capital		Total share capital at 31 March 2011	454	5,068
capital premium capital			t year. The nomir	nal value of each
Balance at 1 January 2010 until 31 March 2011 5 068 196 929 201 997				
		Balance at 1 January 2010 until 31 March 2011	196,929	201,997

19 All amounts in thousands of USD

21. Reserves

_	Statutory reserve	Stock option reserve	Hedging reserve	Translation reserve	Total reserves
Balance at 1 January 2010	1,267	1,415	(8,480)	11,380	5,582
Change on cash flow hedges			4,457		4,457
Share option charge for the period		529			529
Change in hedge of a net investment				2,879	2,879
Transl. diff. of foreign operations				(12,027)	(12,027)
Balance at 1 January 2011	1,267	1,944	(4,023)	2,232	1,420
Change on cash flow hedges			(38)		(38)
Share option charge for the period		130			130
Change in hedge of a net investment				(984)	(984)
Transl. diff. of foreign operations				9,874	9,874
Balance at 31 March 2011	1,267	2,074	(4,061)	11,122	10,402

22. Retained earnings

	Retained earnings
At 1 January 2010	103,647
Net profit	34,866
At 1 January 2011	138,513
Net profit	7,555
Balance at 31 March 2011	146,068

23. Stock option contracts and obligations to increase share capital

The following share-based payment arrangements were in existence at balance sheet date:

0 17 0		Grant/Issue		Exercise	Fair value at grant date
_	Number	date	Exercise date	price DKK	DKK
Issued to President and CEO	1,250,000	5.2.2007	1.12.2011	7.8	5.5
Issued to Executive Management	1,540,000	5.2.2007	1.12.2011	7.8	5.5
Issued to Management team	1,750,000	23.2.2008	23.2.2012	6.9	5.5
Issued to Executive Management	500,000	15.7.2008	15.7.2012	5.4	5.5
Issued to Management team	200,000	2.3.2009	2.3.2013	4.4	5.2
Issued to Management team	300,000	15.12.2009	15.12.2013	5.2	5.2
Issued to Management team	300,000	2.1.2010	2.1.2014	5.3	5.8
Issued to Management team	50,000	26.5.2010	26.5.2014	8.5	8.5
Issued to Management team	100,000	29.7.2010	29.7.2014	8.7	8.7
Issued to Management team	200,000	22.10.2010	22.10.2014	10.7	10.7
Issued to Management team	100,000	21.2.2011	21.2.2014	9.5	9.0
Issued to Management team	100,000	22.3.2011	22.3.2014	8.7	8.6
Total issued option contracts	6,390,000				

Estimated remaining cost due to the stock option contracts are 0.8 million which will be expensed over the next four years, there of 0.6 million in 2011. An expense of 0.1 million is recognised in the Income Statement for the period.

24. Borrowings

_	31.3.2011		31.12.2010	
_	Current	Non-current	Current	Non-current
Loans in USD	11,422	83,251	13,797	83,085
Loans in EUR	3,429	55,957	13,218	71,219
Other borrowings	1,818	4,074	1,822	4,074
	16,669	143,282	28,837	158,378

Aggregated maturities of borrowings are as follows:

	31.3.2011	31.12.2010
In 1.4.2011 - 31.3.2012 / 2011	16,669	28,837
In 1.4.2012 - 31.3.2013 / 2012	15,699	28,656
In 1.4.2013 - 31.3.2014 / 2013	20,287	27,835
In 1.4.2014 - 31.3.2015 / 2014	20,437	20,545
In 1.4.2015 - 31.3.2016 / 2015	86,859	81,342
	159,951	187,215

In March Össur signed an agreement with three international banks, ING Bank, Nordea and SEB on long-term financing in the amount of USD 231 million, thereof USD 111 million revolving credit facility. The financing is for five years, maturing in 2016. Interest terms are subject to a margin grid, changing in line with financial leverage. The initial average interest terms are 145 bps + LIBOR/EURIBOR. Shares in Össur hf. and major subsidiaries are pledged against these loans.

25. Other financial liabilities

As part of the refinancing, Össur closed its interest rate swap agreement, which had a negative value of USD 5.4 million (2010: 4.6 million). The swap remains effective and the cost will be expensed during the next seven quarters. A new interest rate swap agreement was signed in April, which results in appr. 50% of the interest payments on new term loan is bearing fixed interest.

26. Deferred tax asset / (liability)

<u>-</u>	31.3.2011	31.12.2010
At beginning of period.	22,480	31,343
Income tax payable for the period	3,094	6,826
Calculated tax for the period	(2,843)	(12,340)
Arising on acquisition of a subsidiary	0	(1,690)
Recognised directly through equity	(756)	(1,380)
Deferred tax recycled from equity to income	35	(91)
Exchange rate differences	42	(188)
_	22,052	22,480

27. Provisions

	31.3.2011		31.12.2010	
	Current	Non-current	Current	Non-current
Warranty (i)	1,003	4,964	1,110	4,653
Other	1,519	55	1,472	65
	2,522	5,019	2,582	4,718

⁽i) The warranty provision represents management's best estimate of the Company's liability under warranties granted on prosthetics products, based on past experience.

	Warranty provisions	Other provisions	Total
At 1 January 2010	4,986	3,444	8,430
Additional provision recognised	4,473	464	4,937
Utilization of provision	(3,696)	(2,210)	(5,906)
Exchange differences	0	(161)	(161)
At 31 December 2010	5,763	1,537	7,300
Additional provision recognised	988	4	992
Utilization of provision	(784)	(3)	(787)
Exchange differences	0	36	36
At 31 March 2011	5,967	1,574	7,541
Non-current	4,964	55	5,019
Current	1,003	1,519	2,522
At 31 March 2011	5,967	1,574	7,541

28. Related party transactions

The Company had no material transactions with related parties during the period.

29. Other liabilities

	31.3.2011	31.12.2010
Accrued expenses	7,876	8,004
Accrued Royalties	502	1,400
Sales tax and VAT	1,2 70	960
Payable due to previous acquisition	2,324	2,324
Interest rate swap contracts, current portion	0	3,200
Other	2,767	3,261
	14,739	19,149

30. Approval of the Consolidated Financial Statements

The Condensed Interim Consolidated Financial Statements were approved by the board of directors and authorised for issue on 4 May 2011.